TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16870959
Drug: Concomitant psychotropic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant psychotropic medications (82% of patients)
Study: 16870959
Drug: Symptoms likely
Normalized name: Pamprin Multi-Symptom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptoms likely targets of polypharmacy (e.g., depression)
Study: 12600855
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg Cu/L water
Study: 12600855
Drug: <0.01 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: <0.01 mg Cu/L water
Study: 10953652
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy with continuous positive airway pressure (CPAP)
Study: 26916657
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A (1.5 ml/s)
Study: 26916657
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B (2.0 ml/s)
Study: 26916657
Drug: Group C
Normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C (3.0 ml/s)
Study: 25318111
Drug: Long duration
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long duration of intravenous (IV) antibiotics (125 hours)
Study: 25318111
Drug: Shorter duration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shorter duration of IV antibiotics (62 hours)
Study: 25318111
Drug: Transition to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transition to oral antibiotics
Study: 22233325
Drug: Base-in prism
Approvals — FDA: no, EMA: no, PMDA: no
Description: Base-in prism treatment
Study: 19578229
Drug: Azithromycin 20
Normalized name: azithromycin 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 20 mg/kg single dose (n=91)
Study: 19578229
Drug: Ciprofloxacin 20
Normalized name: ciprofloxacin 200 MG in 20 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 20 mg/kg single dose (n=89)
Study: 12806460
Drug: Oral artemisinin
Normalized name: artemisinin
DrugBank: Artemisinin (DB13132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral artemisinin (various doses for one day)
Study: 12806460
Drug: Primaquine (30mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primaquine (30mg daily for 7 days)
Study: 12806460
Drug: Primaquine (30mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primaquine (30mg daily for 5 days)
Study: 12806460
Drug: Chloroquine (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine (single dose)
Study: 2002231
Drug: Erythromycin base
Normalized name: Erythromycin base
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythromycin base 250 mg b.i.d. for 18 months
Study: 6405417
Drug: Doxycycline (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline (200 mg) taken at bedtime
Study: 25270275
Drug: Lower hemoglobin
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower hemoglobin threshold (transfusion at 7 g/dL or less)
Study: 25270275
Drug: Higher hemoglobin
Normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher hemoglobin threshold (transfusion at 9 g/dL or less)
Study: 20623992
Drug: Panitumumab plus
Normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Panitumumab plus chemotherapy (intravenous panitumumab 6 mg/kg every 2 weeks)
Study: 20623992
Drug: Panitumumab plus
Normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Panitumumab plus oxaliplatin-based chemotherapy (FOLFOX4)
Study: 20623992
Drug: Panitumumab plus
Normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Panitumumab plus irinotecan-based chemotherapy (FOLFIRI)
Study: 20623992
Drug: Panitumumab monotherapy
Normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Panitumumab monotherapy plus best supportive care
Study: 16152826
Drug: Ganshao Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganshao Capsule (GSC) for 8 weeks
Study: 16152826
Drug: Ganshao Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganshao Capsule (GSC) followed by Clomiphene (CC) for ovulation induction
Study: 16152826
Drug: Clomiphene (CC)
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene (CC) for ovulation induction after GSC
Study: 14660449
Drug: Single drop
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single drop of 2.5% povidone‐iodine ophthalmic solution at birth
Study: 14660449
Drug: Double drop
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double drop of 2.5% povidone‐iodine ophthalmic solution (one at birth, one at discharge)
Study: 10664920
Drug: Repaglinide (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repaglinide (4 mg single dose)
Study: 9204351
Drug: iopromide 300
Normalized name: IOPROMIDE 300mgI/ml INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: iopromide 300 mg I/ml
Study: 31016447
Drug: iopromide 370
Normalized name: IOPROMIDE 370mgI/ml INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: iopromide 370 mg I/ml
Study: 8995474
Drug: iomeprol 400
Normalized name: Iomeprol 400 MG/1 ML Injection Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: iomeprol 400 mg I/ml
Study: 28366039
Drug: OTC 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: OTC 1% colloidal oatmeal cream
Study: 28366039
Drug: Prescription barrier
Normalized name: BARRIER
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prescription barrier cream
Study: 22963270
Drug: Yoga intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Yoga intervention (twice a week at 30 minutes/session for 8 weeks)
Study: 20084934
Drug: Galvanism penetration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galvanism penetration of traditional Chinese medicine, ultrasonic wave and manipulation
Study: 8390288
Drug: Tc‐99m‐labelled BW
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tc‐99m‐labelled BW 431/26 intact antibody
Study: 29748010
Drug: Chemotherapy +
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy + pelareorep (4.5 × 10^10 TCID50, days 1-3 every 21 days)
Study: 29748010
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (pemetrexed [500 mg/m2, non-squamous] or docetaxel [75 mg/m2], day 1 every 21 days)
Study: 27240903
Drug: 4 weeks
Normalized name: risperiDONE 75 mg/4 weeks intramuscular powder for injection, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 weeks of sofosbuvir (400 mg), velpatasvir (100 mg), and GS‐9857 (100 mg)
Study: 27240903
Drug: 6 weeks
Normalized name: perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 6 weeks of sofosbuvir (400 mg), velpatasvir (100 mg), and GS‐9857 (100 mg)
Study: 27240903
Drug: 6 or
Normalized name: Serc-16 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 or 8 weeks of sofosbuvir (400 mg), velpatasvir (100 mg), and GS‐9857 (100 mg)
Study: 27240903
Drug: 8 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8 weeks of sofosbuvir (400 mg), velpatasvir (100 mg), and GS‐9857 (100 mg)
Study: 19941345
Drug: Median compound
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Median compound muscle action potential (CMAP) amplitude and median motor latency
Study: 18285606
Drug: Targeted anticancer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted anticancer agents (various agents, specific dosages and durations not provided)
Study: 15678039
Drug: Peak creatine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peak creatine kinase MB level < 25 ng/mL
Study: 15678039
Drug: Peak creatine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peak creatine kinase MB level ≥ 100 ng/mL
Study: 10385364
Drug: Splenectomy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Splenectomy with immunotherapy in patients with high IAP levels (>580 microg/ml)
Study: 10385364
Drug: Preservation of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preservation of the spleen with immunotherapy in patients with lower IAP values
Study: 30787634
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg triamcinolone (T20)
Study: 30787634
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg triamcinolone (T40)
Study: 30787634
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg methylprednisolone (M20)
Study: 30787634
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg methylprednisolone (M40)
Study: 7970954
Drug: HAV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAV vaccine (Group A, 6 units)
Study: 7970954
Drug: HAV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAV vaccine (Group B, 13 units)
Study: 7970954
Drug: HAV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAV vaccine (Group C, 25 units)
Study: 11563435
Drug: Medication treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication treatment for pathologic gambling disorder (PGD) in geriatric patients
Study: 11563435
Drug: Nonpharmacologic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonpharmacologic treatment
Study: 29378708
Drug: Plazomicin 15
Normalized name: plazomicin
DrugBank: Plazomicin (DB12615)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Plazomicin 15 mg/kg
Study: 30248987
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein isolate (25 g of crude protein)
Study: 30248987
Drug: Soy protein
Normalized name: Soy Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy protein isolate (25 g of crude protein)
Study: 30248987
Drug: Insect protein
Normalized name: Insect protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insect protein isolate (25 g of crude protein)
Study: 24824991
Drug: Group treatment
Normalized name: Allergenic Extracts Intradermal Kit [9 SO. GRASS GROUP TREATMENT SET]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group treatment using the Lidcombe Program
Study: 24824991
Drug: Individual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual treatment using the Lidcombe Program
Study: 22258267
Drug: Oral liquid
Normalized name: ACAI ORAL LIQUID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral liquid and perceived gastric liquid preloads
Study: 17632215
Drug: Chlorpromazine (200-800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpromazine (200-800 mg/d)
Study: 12392239
Drug: Deep acupuncture
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep acupuncture treatment
Study: 12392239
Drug: Superficial (placebo)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Superficial (placebo) acupuncture treatment
Study: 2268811
Drug: Four doses
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four doses of cefazolin
Study: 2268811
Drug: One dose
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One dose of cefazolin and three doses of placebo
Study: 31689865
Drug: Contact needle
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contact needle therapy (CNT) added to usual care
Study: 26503139
Drug: Girls First
Normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Girls First (combination of Girls First Resilience Curriculum and Girls First Health Curriculum)
Study: 11133627
Drug: Clonidine (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (n = 20): interscalene block with 40 mL of 0.5% bupivacaine with epinephrine and 150 microg (=1 mL) of clonidine, completed by 1 mL of 0.9% saline IM.
Study: 11133627
Drug: Control (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (n = 20): interscalene block with 40 mL of 0.5% bupivacaine with epinephrine and 1 mL of 0.9% saline, completed by 150 microg (=1 mL) of clonidine IM.
Study: 11133627
Drug: Placebo (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (n = 20): interscalene block with 40 mL of 0.5% bupivacaine with epinephrine (1/200000) and 1 mL of 0.9% saline, completed by 1 mL of 0.9% saline IM in the controlateral shoulder.
Study: 2525470
Drug: Fenretinide (HPR)
Normalized name: FENRETINIDE
DrugBank: Fenretinide (DB05076)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenretinide (HPR) 300 mg daily for 6 months
Study: 2525470
Drug: Fenretinide (HPR)
Normalized name: FENRETINIDE
DrugBank: Fenretinide (DB05076)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenretinide (HPR) 200 mg daily for 6 months, then 200 mg for another 6 months
Study: 26670370
Drug: Levothyroxine capsules
Normalized name: levothyroxine Oral Capsule
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levothyroxine capsules with esomeprazole (80 mg)
Study: 26670370
Drug: Levothyroxine tablets
Normalized name: levothyroxine Oral Tablet
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levothyroxine tablets with esomeprazole (80 mg)
Study: 26670370
Drug: Levothyroxine capsules
Normalized name: levothyroxine Oral Capsule
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levothyroxine capsules after esomeprazole administration
Study: 26670370
Drug: Levothyroxine tablets
Normalized name: levothyroxine Oral Tablet
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levothyroxine tablets after esomeprazole administration
Study: 26670370
Drug: Levothyroxine capsules
Normalized name: levothyroxine Oral Capsule
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levothyroxine capsules without esomeprazole
Study: 26670370
Drug: Levothyroxine tablets
Normalized name: levothyroxine Oral Tablet
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levothyroxine tablets without esomeprazole
Study: 21820424
Drug: Propylthiouracil (PTU)
Normalized name: Propylthiouracil
DrugBank: Propylthiouracil (DB00550)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propylthiouracil (PTU) treatment for 6 weeks and 12 weeks
Study: 18500081
Drug: Cyclosporine 0.05%
Normalized name: CYCLOSPORINE 0.05% (PF) EMULSION,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine 0.05% drops twice daily for 3 months
Study: 18500081
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard postoperative LASIK medication)
Study: 16990383
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no aspiration or sham injection)
Study: 15160543
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml of 2% lignocaine hydrochloride gel at 4 degrees C
Study: 15160543
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml of 2% lignocaine hydrochloride gel at 22 degrees C
Study: 8020031
Drug: Low-dose warfarin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose warfarin (INR = 1.5-2.7)
Study: 8020031
Drug: Aspirin, 325
Normalized name: Aspirin, 325 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin, 325 mg/day
Study: 8020031
Drug: Aspirin, 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin, 75 mg/day
Study: 8020031
Drug: Indobufene, 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indobufene, 100 mg bid
Study: 8020031
Drug: Aspirin or
Normalized name: aspirin Oral Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin or indobufene or nothing
Study: 3963031
Drug: Alcohol with
Normalized name: GNP 70% Isopropyl Alcohol with Wintergreen Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol with drug treatment
Study: 31299766
Drug: Abobotulinum toxin‐A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abobotulinum toxin‐A injection (Group 1, n=20)
Study: 27583688
Drug: Vandetanib (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vandetanib (100 mg daily) with platinum (cisplatin or carboplatin) and etoposide
Study: 26374703
Drug: Minocycline (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline (100 mg once daily, increased to 200 mg at two weeks)
Study: 19785978
Drug: Drug court
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug court as usual
Study: 17195727
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment groups (UCPP and CU)
Study: 12855087
Drug: Virtual reality
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual reality distraction intervention during chemotherapy treatment
Study: 12855087
Drug: No distraction
Approvals — FDA: no, EMA: no, PMDA: no
Description: No distraction intervention (control condition) during alternate chemotherapy treatment
Study: 8637514
Drug: TNFR:Fc (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNFR:Fc (0.15 mg/kg)
Study: 8637514
Drug: TNFR:Fc (0.45
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNFR:Fc (0.45 mg/kg)
Study: 8637514
Drug: TNFR:Fc (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNFR:Fc (1.5 mg/kg)
Study: 1888816
Drug: Renzapride (0.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renzapride (0.5, 1.0, or 2.0 mg)
Study: 29684391
Drug: Nitrofurantoin 100
Normalized name: nitrofurantoin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrofurantoin 100 mg twice daily for 7 days preoperatively
Study: 12568832
Drug: Oral E2,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral E2, 1 mg
Study: 12568832
Drug: Oral E2,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral E2, 1 mg plus gestodene, 25 microg
Study: 12568832
Drug: Transdermal 17beta‐E2,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal 17beta‐E2, 50 microg
Study: 11007679
Drug: Atrial natriuretic
Normalized name: Atrial natriuretic factor
DrugBank: Atrial natriuretic peptide (DB15591)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrial natriuretic peptide (ANP) - anaritide, 0.2 microgram/kg/min, 24-hour infusion
Study: 6695841
Drug: Medium and
Normalized name: blood pressure test kit medium and large cuffs MISCELL KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium and large meals (greater than or equal to 35% of daily energy needs)
Study: 6695841
Drug: All meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: All meal sizes (15 to 75% of daily energy requirements)
Study: 20650444
Drug: Best medical
Normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best medical treatment plus renal artery stenting
Study: 10584049
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea extract (50 mg caffeine and 90 mg epigallocatechin gallate)
Study: 19705245
Drug: 16 mg
Normalized name: escin 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 mg dexamethasone
Study: 25793707
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg sodium valproate (patients with aura)
Study: 25793707
Drug: 16 mg
Normalized name: escin 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 mg dexamethasone (patients with aura)
Study: 17476567
Drug: Atrial natriuretic
Normalized name: Atrial natriuretic factor
DrugBank: Atrial natriuretic peptide (DB15591)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrial natriuretic peptide (ANP) infusion during hyperglycaemia
Study: 15221621
Drug: Proximal steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proximal steroid injections (betamethasone)
Study: 15221621
Drug: Distal steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Distal steroid injections (betamethasone)
Study: 8502438
Drug: Narcotic analgesic
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narcotic analgesic (standard intervention)
Study: 3545642
Drug: Lipid infusion
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid infusion into the duodenum
Study: 3545642
Drug: Lipid infusion
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid infusion into the ileum
Study: 27000249
Drug: Subcutaneous interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous interferon beta‐1a (SC IFNB‐1a) 44 μg three times weekly
Study: 25783198
Drug: Low-dose multislice
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose multislice computed tomography (MSCT) screening
Study: 15526804
Drug: salmeterol/fluticasone combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: salmeterol/fluticasone combination 50/500mcg bid
Study: 11212999
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol (50 microg every 6 h)
Study: 9043898
Drug: Humegon (FSH/LH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Humegon (FSH/LH ratio 1:1) via subcutaneous (s.c.) administration
Study: 9043898
Drug: Humegon (FSH/LH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Humegon (FSH/LH ratio 1:1) via intramuscular (i.m.) administration
Study: 9043898
Drug: Normegon (FSH/LH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normegon (FSH/LH ratio 3:1) via subcutaneous (s.c.) administration
Study: 9043898
Drug: Normegon (FSH/LH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normegon (FSH/LH ratio 3:1) via intramuscular (i.m.) administration
Study: 9043898
Drug: Both preparations
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both preparations (Humegon and Normegon)
Study: 7779855
Drug: BT563 (murine
Approvals — FDA: no, EMA: no, PMDA: no
Description: BT563 (murine anti-interleukin-2 receptor monoclonal antibody)
Study: 7779855
Drug: Murine monoclonal
Normalized name: 131I-BC8 monoclonal antibody (Anti-CD45 murine monoclonal antibody radiolabeled with 131I
DrugBank: Apamistamab iodine I-131 (DB16748)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Murine monoclonal CD3 antibody
Study: 7779855
Drug: BT563 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BT563 treatment
Study: 31322086
Drug: Meldonium plus
Normalized name: meldonium
DrugBank: Meldonium (DB13723)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meldonium plus standard antianginal and antiarrhythmic therapy for 2 months